{"id":"early-sequential-nephron-blockade","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Acute kidney injury"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach combines agents that block different steps of the RAAS pathway—typically starting with ACE inhibitors or ARBs, followed by aldosterone antagonists and/or direct renin inhibitors—to achieve more complete suppression of the system. By blocking the RAAS at multiple sequential sites early in disease progression, the strategy aims to prevent progressive nephron loss and slow the decline of renal function in chronic kidney disease.","oneSentence":"Early sequential nephron blockade is a therapeutic strategy that sequentially inhibits multiple points in the renin-angiotensin-aldosterone system (RAAS) to reduce renal injury and proteinuria.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:36:05.959Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic kidney disease with proteinuria"},{"name":"Diabetic nephropathy"}]},"trialDetails":[{"nctId":"NCT04465123","phase":"PHASE3","title":"Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-08-13","conditions":"Acute Heart Failure, Acute Kidney Injury","enrollment":100},{"nctId":"NCT04163588","phase":"PHASE3","title":"Sequential Nephron Blockade in Acute Heart Failure","status":"UNKNOWN","sponsor":"Policlinico Casilino ASL RMB","startDate":"2019-10-01","conditions":"Acute Heart Failure","enrollment":310},{"nctId":"NCT04062760","phase":"PHASE4","title":"Safety and Efficacy of Early, seQUential Oral dIuretic Nephron blockAde In Acute Heart Failure","status":"UNKNOWN","sponsor":"University of Parma","startDate":"2019-12-01","conditions":"Acute Heart Failure","enrollment":206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Early sequential nephron blockade","genericName":"Early sequential nephron blockade","companyName":"University of Parma","companyId":"university-of-parma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Early sequential nephron blockade is a therapeutic strategy that sequentially inhibits multiple points in the renin-angiotensin-aldosterone system (RAAS) to reduce renal injury and proteinuria. Used for Chronic kidney disease with proteinuria, Diabetic nephropathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}